CURIS- Time to Assess Value Beyond Erivedge!
Oral PI3K, BTK, Bcl-2 inhibitors are set to bring a change in treatment paradigm of hematological malignancies (CLL, iNHL, ALL). Curis’s (CRIS) pipeline consists of a marketed drug Erivedge (L in US, R in EU/other, vismodegib, HedgeHog pathway inhibitor) and CUDC-907 (PI3K/HDAC dual inhibitor, PhI) in PhI besides other products. BTK, PI3K and HDAC are clinically validated targets for treating leukemia’s. Current SoC includes IV/SC mAbs (Rituxan/MabThera, Arzerra) in combinations with chemotherapy. There remains an unmet need for pts who are resistant or can not tolerate these treatment options. There are not too many unpartnered PI3K inhibitors in the pipeline and early promising data could trigger………. For more details, please read our report released on 11th February. 2013 on CRIS titled “Time to Assess Value Beyond Erivedge!”
